Is it safe to start testosterone replacement therapy in a 65-year-old man with chronic kidney disease stage 3a?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Testosterone Replacement Therapy in CKD Stage 3a: Safety Assessment

Testosterone replacement therapy can be safely initiated in a 65-year-old man with CKD stage 3a if he has documented hypogonadism (confirmed low testosterone on two separate morning measurements), though close monitoring for specific adverse effects is essential.

Evidence-Based Safety Profile

The most recent and highest-quality evidence from a 2026 propensity-matched cohort study specifically examining TRT in CKD patients (stages 3-5) demonstrated reduced all-cause mortality (HR 0.78,95% CI 0.63-0.98) with no increased risk of cardiovascular events, prostate cancer, or dementia over 5 years of follow-up 1. This directly addresses your patient population and represents the strongest evidence available for this specific clinical scenario.

Key Safety Considerations in CKD

Cardiovascular Safety

  • The 2020 American College of Physicians guideline notes that trials were not powered to assess cardiovascular events and often excluded men at increased risk 2
  • However, the 2026 CKD-specific study found no excess cardiovascular risk 1
  • The 2004 NEJM guideline emphasizes that no large-scale, long-term studies had established definitive cardiovascular safety at that time 3, but more recent evidence has been reassuring

CKD-Specific Risks to Monitor

Erythrocytosis is the most reproducible adverse effect:

  • Occurs in approximately 17% of treated patients vs. 3.3% in controls 4
  • TRT stimulates erythropoiesis, which can be problematic in CKD patients who may already have altered hematologic parameters
  • Monitor hemoglobin and hematocrit closely—this is your primary safety concern

Fluid Retention and Hypertension:

  • TRT may exacerbate fluid retention in CKD patients 5
  • Blood pressure monitoring is essential, particularly in stage 3a CKD where cardiovascular comorbidities are common

Renal Function:

  • Emerging data suggest potential renoprotective effects with preserved or improved eGFR in treated patients 6
  • However, acute kidney injury signals have been noted (2.3% vs. 1.5% in controls) 4
  • Monitor eGFR regularly

Clinical Benefits in CKD Population

The evidence specifically in CKD patients demonstrates meaningful improvements:

  • Enhanced muscle strength and grip strength 7
  • Improved quality of life scores (SF-36, AMS) 7
  • Better hematologic parameters (though requiring monitoring) 7
  • Reduced mortality in the CKD-specific cohort 1

Practical Implementation Algorithm

1. Confirm Hypogonadism

  • Two separate fasting morning total testosterone measurements
  • Document symptoms (sexual dysfunction, fatigue, muscle weakness, depression)
  • CKD stage 3a alone does not justify TRT without confirmed biochemical hypogonadism

2. Exclude Contraindications

  • Active prostate cancer
  • Severe heart failure (NYHA Class IV)
  • Untreated severe obstructive sleep apnea
  • Baseline hematocrit >50%

3. Choose Formulation

  • Transdermal testosterone gel is preferred over intramuscular injections 6
  • Provides stable physiological levels without supraphysiological peaks
  • Lower risk of excessive erythrocytosis compared to injections

4. Monitoring Protocol

First 3 months (monthly):

  • Hemoglobin/hematocrit (primary safety parameter)
  • Serum creatinine/eGFR
  • Blood pressure
  • Testosterone levels (target physiological range, not supraphysiological)

After stabilization (every 3-6 months):

  • Same parameters as above
  • PSA (if age-appropriate)
  • Lipid panel
  • Liver function tests

5. Dose Adjustment Triggers

  • Hold therapy if: Hematocrit >54%, acute decline in eGFR >25%, uncontrolled hypertension
  • Reduce dose if: Hematocrit 50-54%, testosterone levels supraphysiological

Critical Pitfalls to Avoid

  1. Don't treat without confirmed hypogonadism: The 2020 ACP guideline notes that approximately 20% of men receiving TRT had testosterone levels >300 ng/dL at baseline 2—this represents inappropriate prescribing

  2. Don't ignore erythrocytosis: This is the most consistent adverse effect and requires proactive monitoring, not reactive management

  3. Don't use intramuscular preparations as first-line: The "roller coaster" effect of IM testosterone 3 combined with supraphysiological peaks increases erythrocytosis risk in CKD patients

  4. Don't assume functional hypogonadism: Obesity and metabolic syndrome can cause reversible testosterone suppression 4—address these first if present

Bottom Line

For your 65-year-old male with CKD 3a and documented hypogonadism, TRT is safe with appropriate monitoring. The CKD-specific mortality benefit 1 and quality of life improvements 7 support treatment, while the absence of increased cardiovascular or oncologic risk in this population 1 provides reassurance. Use transdermal formulations and monitor hematocrit monthly during initiation—this is your primary safety concern in the CKD population.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.